The role of toll-like receptors in chronic B-cell malignancies.
Toll-like receptors (TLR) are key players in host defence from infection. They recognize a specific set of molecular patterns of microbial origin, immediately trigger an innate immune response, and bridge innate and adaptive immunity. TLR have also been shown to play a role in tumor development. In this context, chronic B-cell malignancies are an interesting example as clonal B lymphocytes remain responsive to and dependent on stimuli originating from the microenvironment which then become crucial for maintaining and propagating the disease. Emerging evidences suggest that, among other microenvironmental elements, TLR ligands may play a role in the pathogenesis of chronic B-cell lymphoid malignancies. Conceivably, their manipulation may find a place in specific settings of treatment of these tumors.
Muzio
Marta
M
Laboratory of Lymphoid Malignancies, Division of Molecular Oncology, San Raffaele Scientific Institute, Milano, Italy.
Bertilaccio
Maria T S
MT
Simonetti
Giorgia
G
Frenquelli
Michela
M
Caligaris-Cappio
Federico
F
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000818:Animals; D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use; D017209:Apoptosis / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D002471:Cell Transformation, Neoplastic / Q000276:immunology*; D015195:Drug Design; D054884:Host-Pathogen Interactions / Q000276:immunology; D006801:Humans; D007113:Immunity, Innate; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D008024:Ligands; D008213:Lymphocyte Activation; D016393:Lymphoma, B-Cell / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000276:immunology; D051379:Mice; D009363:Neoplasm Proteins / Q000276:immunology / Q000502:physiology*; D015398:Signal Transduction; D051193:Toll-Like Receptors / Q000819:agonists / Q000235:genetics / Q000276:immunology / Q000502:physiology*
D000276:Adjuvants, Immunologic; D000970:Antineoplastic Agents; D008024:Ligands; D009363:Neoplasm Proteins; D051193:Toll-Like Receptors